Complement Biology Moves From Background Immunology to Neurologic Treatment Target
Complement has shifted from an abstract arm of innate immunity to a practical therapeutic target in neurology. In the nervous system, its role is double-edged: it supports host defense and tissue homeostasis, yet abnormal activation can amplify autoimmune injury and contribute to degenerative change. The review places this tension at the center of modern neurologic drug development, where investigators are no longer asking whether complement matters, but how selectively it should be modulated and in which diseases the pathway is truly driving pathology.
In autoimmune neurologic disorders, complement is most clearly implicated when pathogenic antibodies fix complement and trigger downstream inflammatory damage. Myasthenia gravis and neuromyelitis optica spectrum disorder sit at the front of that therapeutic wave, and the growing number of approved agents in these settings reflects how directly the cascade can be intercepted. Blocking complement can prevent membrane injury and inflammatory amplification before irreversible neurologic disability accumulates. The logic is biologically clean, but the clinical tradeoff is not simple, because the same pathway helps clear altered, damaged, or senescent cells and contributes to immune surveillance.
Why Proximal Blockade Carries Both Appeal and Risk
The review draws a sharp line between distal and proximal complement inhibition. Distal blockade can preserve more upstream complement activity while limiting the terminal injury complex, whereas proximal inhibition reaches earlier in the cascade and may suppress a broader span of effector functions. That broader reach is attractive in diseases fueled by persistent complement activation, yet it also raises the risk of invasive infection and of disrupting physiologic functions that the nervous system and peripheral tissues still depend on.
One sentence captures the central hazard plainly: suppressing complement too early in the cascade can remove protection as well as pathology. In practical terms, this is why emerging therapies aimed at components such as C1 must be weighed against infection risk and the possibility of collateral immune dysfunction. The need for careful patient selection is not theoretical. If complement is acting as a damaging effector in one disorder and as a protective homeostatic system in another, then a one-size-fits-all strategy is likely to fail at the bedside.
Multiple Sclerosis, Alzheimer Disease, and ALS Enter the Conversation
The review extends beyond the best-established autoimmune indications and toward a wider neurologic horizon. Experimental evidence points to complement involvement in multiple sclerosis, Alzheimer disease, and amyotrophic lateral sclerosis, suggesting that complement-targeted therapy may eventually move from rare antibody-mediated diseases into more common inflammatory and degenerative conditions. This is a major conceptual shift, because it frames complement not only as a mediator of acute immune attack, but also as a participant in synaptic and tissue remodeling.
That broader reach comes with a warning embedded in the biology itself. Experimental data indicate that specific complement components can be tissue-protective in some central nervous system diseases, including Alzheimer disease and multiple sclerosis. Broad inhibition could therefore blunt damaging inflammation while simultaneously removing signals that support normal circuit maintenance or compensation. The review’s message is direct: pathway-selective modulation is more plausible than blanket suppression if the field wants durable benefit without unnecessary neurologic cost.
Synapses, Microglia, and the Cost of Overactive Pruning
Complement biology in the central nervous system is not limited to classic immune injury. The pathway also participates in brain development, synapse elimination, and nervous system homeostasis. Those functions are part of normal biology, yet they also provide a mechanism by which dysregulated complement activity can promote inappropriate synaptic pruning or neural network disruption. In neurodegenerative disease, that same machinery may be co-opted into chronic injury.
This is where the review becomes especially relevant for clinicians trying to interpret the therapeutic pipeline. If complement contributes to synapse elimination and microglia-mediated pruning, then treatment decisions are not just about inflammation in the abstract; they are about preserving neural circuitry. The biology explains why a drug that is beneficial in one autoimmune condition may not translate neatly into a degenerative disorder. It also explains why future trial design will need to separate true disease modification from simple suppression of inflammatory biomarkers.
The Pipeline Is Expanding Faster Than the Diagnostic Playbook
A robust stream of phase I–III studies is now testing biologic agents that inhibit proximal or distal complement components. Several FDA-approved agents are already available, and others are moving through clinical development. The review argues, implicitly but forcefully, that the field has outgrown purely mechanistic enthusiasm. With more therapies entering neurologic care, clinicians will need systematic diagnostic guidance to decide who should receive complement inhibition, when it should be started, and which biomarker profile best predicts response.
The absence of reliable, disease-specific biomarkers remains one of the clearest bottlenecks. Without them, treatment selection risks becoming empirical rather than precision-based. A patient with complement-fixing antibodies may be an obvious candidate in one disorder, while another with more ambiguous inflammatory biology may gain little and incur avoidable infectious risk. Biomarker development therefore sits alongside drug discovery as a core requirement for personalized use of this class.
Safety, Selectivity, and the Limits of a Broad-Spectrum Strategy
The expanding therapeutic class is crowded into a neurology space already populated by biologic agents aimed at other autoimmunity pathways. Complement inhibition will have to compete on efficacy, safety, and mechanistic fit. Because proximal blockade can interfere with physiologic complement functions, the safety threshold may be especially important in patients who already carry infection susceptibility or whose disease biology depends partly on complement-mediated clearance.
One practical consequence follows from this review: neurologists will need to think less in terms of “complement on or off” and more in terms of pathway geography. Early components such as C1, terminal effector elements, and disease-specific complement signatures may each demand different therapeutic logic. The review closes not with certainty, but with a clear clinical demand: anti-complement therapy is poised to reshape autoimmune neurology, yet its success will depend on matching the right pathway target to the right disease biology and on proving that selective inhibition can protect the nervous system without compromising immune defense.